Alvotech and DR. Reddy’s Announce FDA Acceptance of Biologic License Application for Avt03, a Proposed Biosimilar to Prolia® and Xgeva®
Alvotech和DR. Reddy’s宣佈FDA接受Avt03生物許可證申請,這是針對Prolia®和Xgeva®的擬議生物仿製藥。
Alvotech and DR. Reddy’s Announce FDA Acceptance of Biologic License Application for Avt03, a Proposed Biosimilar to Prolia® and Xgeva®
Alvotech和DR. Reddy’s宣佈FDA接受Avt03生物許可證申請,這是針對Prolia®和Xgeva®的擬議生物仿製藥。
譯文內容由第三人軟體翻譯。
評論(0)
請選擇舉報原因